Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.

作者信息

William Anthony D, Lee Angeline C-H

机构信息

S*BIO Pte Ltd, 250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101; Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology, and Research (A*STAR), 11 Biopolis Way, Helios Block, #03-08, Singapore 138667, Singapore.

S*BIO Pte Ltd, 250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101.

出版信息

Chimia (Aarau). 2015;69(3):142-5. doi: 10.2533/chimia.2015.142.

DOI:10.2533/chimia.2015.142

PMID:26507218

Abstract

The powerful olefin metathesis reaction was employed for the construction of late-phase clinical agents SB1317 and SB1518. In both cases RCM seems to proceed only in the presence of an acid and to predominantly furnish trans isomers. In case of SB1518 it proceeded in the presence of acid HCl, while for SB1317, it mainly proceeds in the presence of TFA (trifluroacetic acid).

摘要

相似文献

Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.

Chimia (Aarau). 2015;69(3):142-5. doi: 10.2533/chimia.2015.142.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.

J Med Chem. 2011 Jul 14;54(13):4638-58. doi: 10.1021/jm200326p. Epub 2011 Jun 15.

Kinetically E-selective macrocyclic ring-closing metathesis.

Nature. 2017 Jan 19;541(7637):380-385. doi: 10.1038/nature20800. Epub 2017 Jan 9.

The role of pacritinib in the management of myelofibrosis.

Expert Rev Hematol. 2014 Jun;7(3):325-32. doi: 10.1586/17474086.2014.905200. Epub 2014 Apr 21.

Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).

J Comput Aided Mol Des. 2012 Apr;26(4):437-50. doi: 10.1007/s10822-012-9572-z. Epub 2012 Apr 22.

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.

Expert Opin Investig Drugs. 2013 Jun;22(6):775-85. doi: 10.1517/13543784.2013.775244. Epub 2013 Feb 26.

Total syntheses of (-)-huperzine Q and (+)-lycopladines B and C.

Angew Chem Int Ed Engl. 2015 Jan 12;54(3):1011-5. doi: 10.1002/anie.201409503. Epub 2014 Oct 30.

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

Leukemia. 2011 Nov;25(11):1751-9. doi: 10.1038/leu.2011.148. Epub 2011 Jun 21.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J Clin Oncol. 2012 Nov 20;30(33):4161-7. doi: 10.1200/JCO.2012.42.5223. Epub 2012 Sep 10.

The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.

Expert Rev Anticancer Ther. 2016 Nov;16(11):1101-1108. doi: 10.1080/14737140.2016.1233061. Epub 2016 Sep 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验